Characterization of piroxicam crystal modifications

International Journal of Pharmaceutics

Volumn 256, Issue 1-2, 2003, Pages 3-15

  Vrecer F ^a   Vrbinc, M ^a   Meden, A ^b  

^a dd   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Characterization; Piroxicam; Polymorphism

Indexed keywords

1,2 DICHLOROETHANE; 2 PROPANOL; ALCOHOL; BENZENE; BENZYL ALCOHOL; CARBON DIOXIDE; CHLOROFORM; DICHLOROMETHANE; METHANOL; PIROXICAM; SOLVENT; TERT BUTYL ALCOHOL; WATER;

CHEMICAL MODIFICATION; CONFERENCE PAPER; CRYSTAL; CRYSTAL STRUCTURE; CRYSTALLIZATION; DISSOLUTION; DRUG SCREENING; HYDROGEN BOND; INFRARED SPECTROMETRY; MECHANICAL STRESS; MELTING POINT; PARAMETER; POLARIZATION; PRIORITY JOURNAL; TEMPERATURE; THERMOSTABILITY; WETTABILITY;

EID: 0037473468     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00057-7     Document Type: Conference Paper

References (21)

1. Altomare A., Burla M.C., Camalli M., Cascarano G., Giacovazzo C., Guagliardi A., Polidori G. J. Appl. Crystallogr. 27:1994;435.
2. 2O. Acta Crystallogr. C40:1984;989-990.
3. Brittain, H.G., Grant, D.J.W., 1999. Effects of polymorphism and solid state solvation on solubility and dissolution rate. In: Brittain, H.G. (Ed.), Polymorphism in Pharmaceutical Solids. Marcel Dekker, New York, pp. 279-330.
4. Burger A., Ramberger R. On the polymorphism of pharmaceuticals and other molecular crystals. I: Theory of thermodynamic rules. Microchim. Acta. 11:1979;259-271.
5. Collect Software, 1998. Nonius, BV, Delft, The Netherlands.
6. Ghan G.A., Lalla J.K. Effect of compressional forces on piroxicam polymorphs. J. Pharm. Pharmacol. 44:1992;678-681.
7. Hall, S.R., King, G.S.D., Stewart, J.M., 1995. The Xtal3.4 User's Manual. University of Western Australia.
8. Herzfeldt C.D., Kummel R. Dissociation constants, solubilities and dissolution rates of some selected nonsteroidal antiinflamatories. Drug Dev. Ind. Pharm. 9:1983;767-793.
9. Janik M., Malarski Z., Mrozinski J., Wajcht J., Zborucki Z. Influence of solvent effect on polymorphism of 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide (piroxicam). J. Crystallogr. Spec. Res. 21:1991;519-522.
10. Kojić-Prodić B., Ružić-Toroš Ž Structure of the anti-inflammatory drug 4-hydroxy-2-methyl-N-2-pyridyl-2H-1λ,2-benzothiazine-3-carboxamide- 1,1-dioxide (piroxicam). Acta Crystallogr. B38:1982;2948-2951.
11. Kozjek F., Golič L., Zupet P., Palka E., Vodopivec P., Japelj M. Physico-chemical properties and bioavailability of two crystal forms of piroxicam. Acta Pharm. Jugosl. 35:1985;275-281.
12. Kuhnert-Brandstätter M., Völlenklee R. Thermoanalytische und IR-spectroskopische Untersuchungen an Polymorphen Arzneistoffen: Acemetacin, Piroxicam, Propranolohydrochlorid and Urapidil. Frasenius Z. Anal. Chem. 322:1985;164-169.
13. Mihalić M., Hofman H., Kajfež F., Kuftinec J., Blažvić N., Žinić M. Physico-chemical and analytical characteristics of piroxicam. Acta Pharm. Jugosl. 32:1982;13-20.
14. Mihalić, M., Hofman, H., Kuftinec, J., Krile, B., Čaplar, V., Kajfež, F., Blažević, N.,1986. Piroxicam. In: Florey, K. (Ed.), Analytical Profiles of Drug Substances, vol. 15. Academic Press, Orlando, pp. 509-531.
15. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326.
16. Pretrišič I., 2001. Study of physical properties of crystal modifications of piroxicam. B.S. Thesis. University of Ljubljana, Faculty of Pharmacy.
17. Reck G., Laban G. Prediction and establishment of a new crystalline piroxicam modification. Pharmazie. 45:1990;257-259.
18. Reck G., Dietz G., Laban G., Günther W., Bannier G., Höhne E. X-ray studies on piroxicam modifications. Pharmazie. 43:1988;477-481.
19. VanKel Industries, 1992. Intrinsic Dissolution Apparatus Operator's Manual.
20. Vrečer F., Srčič S., Šmid-Korbar J. Investigation of piroxicam polymorphism. Int. J. Pharm. 68:1991;35-41.
21. Wang, H., Robertson, B.E., 1985. In: Wilson, A.J.C. (Ed.), Structure and Statistics in Crystallography. Adenine Press, New York.